HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

H. Lundbeck A/S

http://www.lundbeck.com

Latest From H. Lundbeck A/S

Lundbeck's Vyepti Launch In US Disappoints In First Half

The coronavirus pandemic held back sales of Lundbeck’s newest product, Vyepti, in the US during the first half, but the company spent less than expected on SG&A because of COVID-19, and increased investments in marketing infrastructure and restructuring R&D.

Sales & Earnings Coronavirus COVID-19

Ovid De-Risks Its Phase III Angelman Program With EU Angelini Partnership

Deals Business Strategies

Triple Joy For European Biotechs As FDA OKs Byfavo

Having secured FDA approval, the UK's Acacia Pharma will market Byfavo, the first new product in the sedation space in decades, which was licensed from Italy's Cosmo and developed by Germany's Paion.

Approvals Strategy

Otsuka’s ADHD Contender Hits Mark In Phase III

Otsuka's novel ADHD therapy moves closer to a potential filing after meeting its endpoint in two Phase III trials, validating a past acquisition and further bolstering the Japanese firm's CNS prospects. 

Neurology Clinical Trials
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abide Therapeutics Inc.
    • Alder Biopharmaceuticals, Inc.
    • Chelsea Therapeutics International, Ltd.
    • Lundbeck La Jolla Research Center
    • Lundbeck Seattle Biopharmaceuticals
    • Ovation Pharmaceuticals, Inc
    • Saegis Pharmaceuticals, Inc.
UsernamePublicRestriction

Register